StreetInsider.com News Articles

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Wed, 26 Aug 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in September:

Citi’s 2026 Biotech Back to School Conference
Date: Wednesday, September 9th, 2026
Location: New York, NY
Format: Fireside chat & 1x1 meetings
Time: 10:40 a.m. ET

Cantor Fitzgerald Global Healthcare Conference 2026
Date: Thursday, September 10th, 2026
Location: New York, NY
Format: Fireside chat & 1x1 meetings
Time: 9:45 a.m. ET

Morgan Stanley 24th

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Wed, 26 Aug 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in September:
Citi’s 2026 Biotech Back to School Conference
Date: Wednesday, September 9th, 2026
Location: New York, NY
Format: Fireside chat & 1x1 meetings
Time: 10:40 a.m. ET
Cantor Fitzgerald Global Healthcare Conference 2026
Date: Thursday, September 10th, 2026
Location: New York, NY
Format: Fireside chat & 1x1 meetings
Time: 9:45 a.m. ET
Morgan Stanley 24th

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Wed, 26 Aug 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in September:
Citi’s 2026 Biotech Back to School Conference
Date: Wednesday, September 9th, 2026
Location: New York, NY
Format: Fireside chat & 1x1 meetings
Time: 10:40 a.m. ET
Cantor Fitzgerald Global Healthcare Conference 2026
Date: Thursday, September 10th, 2026
Location: New York, NY
Format: Fireside chat & 1x1 meetings
Time: 9:45 a.m. ET
Morgan Stanley 24th

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Wed, 26 Aug 2026 16:05:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in September:
Citi’s 2026 Biotech Back to School Conference
Date: Wednesday, September 9th, 2026
Location: New York, NY
Format: Fireside chat & 1x1 meetings
Time: 10:40 a.m. ET
Cantor Fitzgerald Global Healthcare Conference 2026
Date: Thursday, September 10th, 2026
Location: New York, NY
Format: Fireside chat & 1x1 meetings
Time: 9:45 a.m. ET
Morgan Stanley 24th

Form 4 Arcus Biosciences, Inc. For: Aug 21 Filed by: Azoy Alexander

Mon, 24 Aug 2026 17:52:00 -0400
si-local-file:///var/storage/secattach/20260824/26969336.html

Form 4 Arcus Biosciences, Inc. For: Aug 21 Filed by: Azoy Alexander

Mon, 24 Aug 2026 17:52:00 -0400
si-local-file:///var/storage/secattach/20260824/26969336.html

Form 144 Arcus Biosciences, Inc. Filed by: Azoy Alexander

Fri, 21 Aug 2026 16:36:00 -0400
si-local-file:///var/storage/secattach/20260821/26961910.html

Form 144 Arcus Biosciences, Inc. Filed by: Azoy Alexander

Fri, 21 Aug 2026 16:36:00 -0400
si-local-file:///var/storage/secattach/20260821/26961910.html

Arcus Biosciences Announces New Employment Inducement Grants

Tue, 11 Aug 2026 16:35:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company’s common stock at an exercise price per share of $28.72, which was the closing price on August 10, 2026, and restricted stock units to acquire a total of 1,450 shares of the Company’s common stock. The equity awards were granted pursuant

Arcus Biosciences Announces New Employment Inducement Grants

Tue, 11 Aug 2026 16:35:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company’s common stock at an exercise price per share of $28.72, which was the closing price on August 10, 2026, and restricted stock units to acquire a total of 1,450 shares of the Company’s common stock. The equity awards were granted pursuant

Arcus Biosciences Announces New Employment Inducement Grants

Tue, 11 Aug 2026 16:35:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company’s common stock at an exercise price per share of $28.72, which was the closing price on August 10, 2026, and restricted stock units to acquire a total of 1,450 shares of the Company’s common stock. The equity awards were granted pursuant

Arcus Biosciences Announces New Employment Inducement Grants

Tue, 11 Aug 2026 16:35:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company’s common stock at an exercise price per share of $28.72, which was the closing price on August 10, 2026, and restricted stock units to acquire a total of 1,450 shares of the Company’s common stock. The equity awards were granted pursuant

Arcus Biosciences (RCUS) PT Raised to $23 at Morgan Stanley

Mon, 10 Aug 2026 08:35:54 -0400
Morgan Stanley analyst Terence Flynn raised the price target on Arcus Biosciences (NYSE: RCUS) to $23.00 (from $22.00) while maintaining a Equalweight rating.

Form SCHEDULE 13D/A Arcus Biosciences, Inc. Filed by: GILEAD SCIENCES, INC.

Fri, 07 Aug 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260807/26891527.html

Form SCHEDULE 13D/A Arcus Biosciences, Inc. Filed by: GILEAD SCIENCES, INC.

Fri, 07 Aug 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260807/26891527.html

Arcus Biosciences (RCUS) PT Raised to $26 at Wells Fargo

Thu, 06 Aug 2026 06:38:41 -0400
Wells Fargo analyst Jason Hass raised the price target on Arcus Biosciences (NYSE: RCUS) to $26.00 (from $23.00) while maintaining a Equal Weight rating.

Arcus Biosciences (RCUS) Tops Q2 EPS by 18c

Wed, 05 Aug 2026 16:51:03 -0400

Arcus Biosciences (NYSE: RCUS) reported Q2 EPS of ($0.72), $0.18 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $41 million versus the consensus estimate of $22.22 million.
For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

Form 10-Q Arcus Biosciences, Inc. For: Jun 30

Wed, 05 Aug 2026 16:12:00 -0400
si-local-file:///var/storage/secattach/20260805/26874426.html

Form 10-Q Arcus Biosciences, Inc. For: Jun 30

Wed, 05 Aug 2026 16:12:00 -0400
si-local-file:///var/storage/secattach/20260805/26874426.html

Form 8-K Arcus Biosciences, Inc. For: Aug 05

Wed, 05 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260805/26874171.html

Form 8-K Arcus Biosciences, Inc. For: Aug 05

Wed, 05 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260805/26874171.html

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Wed, 05 Aug 2026 16:05:00 -0400

Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including three new clinical trial collaborations that advance distinct casdatifan-based combinations

New research published in Nature, evaluating patients with advanced ccRCC who were treated with casdatifan, provided the first data that comprehensively connect clinical outcomes for patients receiving a HIF-2α inhibitor with peripheral biomarker changes and associated tumor biology

Multiple ARC-20 data readouts for casdatifan across lines of therapy are expected in the second half of 2026, including initial efficacy data for casdatifan plus zimberelimab in first-line, progression-free

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Wed, 05 Aug 2026 16:05:00 -0400

Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including three new clinical trial collaborations that advance distinct casdatifan-based combinations

New research published in Nature, evaluating patients with advanced ccRCC who were treated with casdatifan, provided the first data that comprehensively connect clinical outcomes for patients receiving a HIF-2α inhibitor with peripheral biomarker changes and associated tumor biology

Multiple ARC-20 data readouts for casdatifan across lines of therapy are expected in the second half of 2026, including initial efficacy data for casdatifan plus zimberelimab in first-line, progression-free

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Wed, 05 Aug 2026 16:05:00 -0400

Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including three new clinical trial collaborations that advance distinct casdatifan-based combinations

New research published in Nature, evaluating patients with advanced ccRCC who were treated with casdatifan, provided the first data that comprehensively connect clinical outcomes for patients receiving a HIF-2α inhibitor with peripheral biomarker changes and associated tumor biology

Multiple ARC-20 data readouts for casdatifan across lines of therapy are expected in the second half of 2026, including initial efficacy data for casdatifan plus zimberelimab in first-line, progression-free

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Wed, 05 Aug 2026 16:05:00 -0400

Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including three new clinical trial collaborations that advance distinct casdatifan-based combinations

New research published in Nature, evaluating patients with advanced ccRCC who were treated with casdatifan, provided the first data that comprehensively connect clinical outcomes for patients receiving a HIF-2α inhibitor with peripheral biomarker changes and associated tumor biology

Multiple ARC-20 data readouts for casdatifan across lines of therapy are expected in the second half of 2026, including initial efficacy data for casdatifan plus zimberelimab in first-line, progression-free